MIT s recent investment in Marksans Pharma underscores the small-cap s hidden gem status, fuelled by its strong presence in stable OTC markets and strategic growth initiatives, signalling promising prospects for revenue and profit expansion.
These smallcap schemes could be at risk as they have lesser exposure to large stocks, cash and cash equivalents (including T-bills), and higher exposure to stocks from the Nifty Microcap 250 Index